Mercado de Salud
Páginas: 37 (9092 palabras)
Publicado: 22 de noviembre de 2015
Indicadores Básicos
Year
Latest
data
External debt stocks (% of GNI)
2007
23,7
External debt stocks (% of GNI)
..
..
GDP (current US$) (billions)
2007
3.615,9
GDP (current US$) (billions)
2007
54.583,8
Latin America & Caribbean
GNI per capita, Atlas method (current
2007
US$)
5.801
WORLD
Year Latest data
GNI per capita, Atlas method (current US$) 2007
7.995
Life expectancyat birth, total (years)
2007
73
Life expectancy at birth, total (years)
2007
69
Population, total (millions)
2007
560,6
Population, total (millions)
2007
6.610,3
Population growth (annual %)
2007
1,2
Population growth (annual %)
2007
1,2
School enrollment, primary (% net)
2006
93,9
School enrollment, primary (% net)
2006
86,4
Surface area (sq. km) (thousands)
200720.421,0
Surface area (sq. km) (thousands)
2007
133.945,8
Source; WORLD BANK
VENTAS FARMACÉUTICAS MUNDIALES
20001 – 2008
(BILLONES DE DÓLARES)
Mercado
Farmaceútico
Mundial (Dolares
corrientes en
Billones)
2001
2002
2003
2004
2005
2006
2007
2008
393
429
499
560
605
648
715
773
Crecimeinto sobre el
11,80% 9,20% 10,20% 7,90% 7,20% 6,80% 6,60% 4,80%
año previo
Source: IMS HealthMarket Prognosis (includes IMS Audited and Unaudited markets)
All information current as of March, 2009
Total mercados globales auditados y no auditados
2008
Tamaño del mercado
US$ Bn
2007
2003-2008
2009
2008-2013
% Crecimiento
const. Us $
% Crecimiento
const. Us $
Carg % Const
US$
Proyección % en
crecimiento
Carg % Const
US$
$ 773,10
4,80%
6,60%
2,5 - 3,5%
3 - 6%
Total mercadosglobales auditados y no auditados
2008
2007
2003-2008
2009
2008-2013
Tamaño del
% Crecimiento
mercado US$ Bn
const. Us $
% Crecimiento
const. Us $
Carg %
Const US$
Proyección % en
crecimiento
Carg %
Const US$
Norte América
311,8
1,40%
4,40%
5,70%
-1 - 0%
_-1 - 2%
Europa
247,5
5,80%
7,10%
6,40%
3 - 4%
3 - 6%
Asia/Africa/Australia
90,8
15,30%
15,00%
13,70%
11 - 12%
11 - 14%Japon
76,6
2,10%
4,20%
2,70%
4 - 5%
1 - 4%
Latin America
46,5
12,60%
12,80%
12,70%
9 - 10%
11 - 14%
Source: IMS Health Market Prognosis, March 2009
2008
rank
(US$)
2008
Sales
(US$
MN)
%
Growth
2008
(LC$)
Global Market
0
724,465
4,4
612,01
3
6,2
612,01
3
6,6
572,65
9
7,2
530,909
7,9
Oncologics
1
48,189
11,3
41,707
15,5
34,772
20,2
28,851
19,1
24,174
17,4Lipid Regulators
2
33,79
-2,3
33,79
-7,1
35,322
7,4
32,788
6,5
30,653
12,6
Respiratory Agents
3
31,271
5,7
24,891
12,3
24,891
11,2
22,304
13,7
19,527
11,1
Antidiabetics
4
24,283
9,6
21,3
10,4
21,309
12,7
18,842
11,6
16,798
9,9
Acid Pump Inhibitors
5
25,751
0,6
25,751
3,3
23,204
4,3
23,204
5,3
21,972
3,9
Angiotensin II Antagonists
6
22,875
12,616,494
13,7
16,494
15
12,136
18,2
12,136
22,8
Antipsychotics
7
20,787
8
20,787
10,9
18,242
11
16,385
11,2
14,693
13,3
Antidepressants
8
20,336
0,6
120,70
7
-7,1
20,707
3,6
19,937
-3,8
20,646
2,1
Anti-epileptics
9
15,2
9,7
15,264
13,6
11,7
10,8
11,578
1
11,578
18,9
Autoimmune agents
10
13,3
16,9
13,32
21
78,837
20,7
8,837
31,2
6,736
43,6
PlateletAggr. Inhibitors
11
11,969
10,3
10,678
8,3
10,678
7,8
98,97
9,9
8,97
18,6
HIV Antivirals
12
10,74
11,9
10,74
11,9
9,286
10,4
8,367
11,4
7,497
16,5
Erythropoietins
13
12,959
-13,9
13,971
-9,1
13,971
11,8
11,605
7,3
11,605
9,6
Non-narcotic analgesics
14
11,161
3,6
10,472
7,9
9,138
3,1
8,755
5,9
8,138
2,4
Narcotic analgesics
15
89,608
8,8
9,60813,2
8,287
-2,2
8,435
2,9
8,188
13,9
Source: IMS Health Market Prognosis, March 2009
2007
%
2006
%
2005
%
2004
%
Sales Growth Sales Growth Sales Growth Sales Growth
(US$
2007
(US$
2006
(US$
2005
(US$
2004
MN)
(LC$)
MN)
(LC$)
MN)
(LC$)
MN)
(LC$)
2008 rank
(US$)
2008 Sales
(US$ MN)
2007 Sales
(US$ MN)
2006 Sales
(US$ MN)
2005 Sales
(US$ MN)
2004 Sales
(US$ MN)
PFIZER
1
44,651...
Year
Latest
data
External debt stocks (% of GNI)
2007
23,7
External debt stocks (% of GNI)
..
..
GDP (current US$) (billions)
2007
3.615,9
GDP (current US$) (billions)
2007
54.583,8
Latin America & Caribbean
GNI per capita, Atlas method (current
2007
US$)
5.801
WORLD
Year Latest data
GNI per capita, Atlas method (current US$) 2007
7.995
Life expectancyat birth, total (years)
2007
73
Life expectancy at birth, total (years)
2007
69
Population, total (millions)
2007
560,6
Population, total (millions)
2007
6.610,3
Population growth (annual %)
2007
1,2
Population growth (annual %)
2007
1,2
School enrollment, primary (% net)
2006
93,9
School enrollment, primary (% net)
2006
86,4
Surface area (sq. km) (thousands)
200720.421,0
Surface area (sq. km) (thousands)
2007
133.945,8
Source; WORLD BANK
VENTAS FARMACÉUTICAS MUNDIALES
20001 – 2008
(BILLONES DE DÓLARES)
Mercado
Farmaceútico
Mundial (Dolares
corrientes en
Billones)
2001
2002
2003
2004
2005
2006
2007
2008
393
429
499
560
605
648
715
773
Crecimeinto sobre el
11,80% 9,20% 10,20% 7,90% 7,20% 6,80% 6,60% 4,80%
año previo
Source: IMS HealthMarket Prognosis (includes IMS Audited and Unaudited markets)
All information current as of March, 2009
Total mercados globales auditados y no auditados
2008
Tamaño del mercado
US$ Bn
2007
2003-2008
2009
2008-2013
% Crecimiento
const. Us $
% Crecimiento
const. Us $
Carg % Const
US$
Proyección % en
crecimiento
Carg % Const
US$
$ 773,10
4,80%
6,60%
2,5 - 3,5%
3 - 6%
Total mercadosglobales auditados y no auditados
2008
2007
2003-2008
2009
2008-2013
Tamaño del
% Crecimiento
mercado US$ Bn
const. Us $
% Crecimiento
const. Us $
Carg %
Const US$
Proyección % en
crecimiento
Carg %
Const US$
Norte América
311,8
1,40%
4,40%
5,70%
-1 - 0%
_-1 - 2%
Europa
247,5
5,80%
7,10%
6,40%
3 - 4%
3 - 6%
Asia/Africa/Australia
90,8
15,30%
15,00%
13,70%
11 - 12%
11 - 14%Japon
76,6
2,10%
4,20%
2,70%
4 - 5%
1 - 4%
Latin America
46,5
12,60%
12,80%
12,70%
9 - 10%
11 - 14%
Source: IMS Health Market Prognosis, March 2009
2008
rank
(US$)
2008
Sales
(US$
MN)
%
Growth
2008
(LC$)
Global Market
0
724,465
4,4
612,01
3
6,2
612,01
3
6,6
572,65
9
7,2
530,909
7,9
Oncologics
1
48,189
11,3
41,707
15,5
34,772
20,2
28,851
19,1
24,174
17,4Lipid Regulators
2
33,79
-2,3
33,79
-7,1
35,322
7,4
32,788
6,5
30,653
12,6
Respiratory Agents
3
31,271
5,7
24,891
12,3
24,891
11,2
22,304
13,7
19,527
11,1
Antidiabetics
4
24,283
9,6
21,3
10,4
21,309
12,7
18,842
11,6
16,798
9,9
Acid Pump Inhibitors
5
25,751
0,6
25,751
3,3
23,204
4,3
23,204
5,3
21,972
3,9
Angiotensin II Antagonists
6
22,875
12,616,494
13,7
16,494
15
12,136
18,2
12,136
22,8
Antipsychotics
7
20,787
8
20,787
10,9
18,242
11
16,385
11,2
14,693
13,3
Antidepressants
8
20,336
0,6
120,70
7
-7,1
20,707
3,6
19,937
-3,8
20,646
2,1
Anti-epileptics
9
15,2
9,7
15,264
13,6
11,7
10,8
11,578
1
11,578
18,9
Autoimmune agents
10
13,3
16,9
13,32
21
78,837
20,7
8,837
31,2
6,736
43,6
PlateletAggr. Inhibitors
11
11,969
10,3
10,678
8,3
10,678
7,8
98,97
9,9
8,97
18,6
HIV Antivirals
12
10,74
11,9
10,74
11,9
9,286
10,4
8,367
11,4
7,497
16,5
Erythropoietins
13
12,959
-13,9
13,971
-9,1
13,971
11,8
11,605
7,3
11,605
9,6
Non-narcotic analgesics
14
11,161
3,6
10,472
7,9
9,138
3,1
8,755
5,9
8,138
2,4
Narcotic analgesics
15
89,608
8,8
9,60813,2
8,287
-2,2
8,435
2,9
8,188
13,9
Source: IMS Health Market Prognosis, March 2009
2007
%
2006
%
2005
%
2004
%
Sales Growth Sales Growth Sales Growth Sales Growth
(US$
2007
(US$
2006
(US$
2005
(US$
2004
MN)
(LC$)
MN)
(LC$)
MN)
(LC$)
MN)
(LC$)
2008 rank
(US$)
2008 Sales
(US$ MN)
2007 Sales
(US$ MN)
2006 Sales
(US$ MN)
2005 Sales
(US$ MN)
2004 Sales
(US$ MN)
PFIZER
1
44,651...
Leer documento completo
Regístrate para leer el documento completo.